Is Journal of Clinical Oncology a Good Journal? The ASCO Flagship for Practice-Changing Oncology

Oncology has four major clinical journals, each tied to a professional society or publishing network:

JCO vs Annals of Oncology: Annals of Oncology (IF 65.4) has the highest IF in clinical oncology and drives ESMO guideline development. If your trial data will directly inform European treatment guidelines, Annals of Oncology may be the better target. For US oncology practice, JCO is the default.

JCO vs Lancet Oncology: Lancet Oncology (IF 35.9) emphasizes global oncology, health policy, and international trials. If your paper has a strong global health dimension, Lancet Oncology may be the better fit. For standard clinical oncology aimed at US and international practitioners, JCO is more natural.

JCO vs JAMA Oncology: JAMA Oncology (IF 20.1) applies JAMA Network editorial standards, strict word limits, mandatory statistical review, Key Points format. If your paper survives JAMA-style compression well, it's a reasonable alternative. JCO allows more clinical detail and reaches a more specialized oncology audience.

In our pre-submission review work with manuscripts targeting Journal of Clinical Oncology, the most common triage problem is oncology that is still too niche-first. The dataset may be good, but the clinical consequence only makes sense to one disease-site community and never expands into a broader oncology decision.

We also see safety, tolerability, and patient-facing tradeoffs buried in supplement tables while the abstract foregrounds efficacy alone. That is a weak JCO signal. Working oncologists do not only ask whether an intervention works. They ask whether the benefit is large enough, stable enough, and tolerable enough to change practice.

The third repeat issue is clinical consequence implied rather than stated. The manuscript shows an effect, but the title, abstract, and early results never say exactly what an oncologist would do differently because of it. JCO is unusually unforgiving on that point because the journal is built around decision-ready oncology, not merely positive oncology.

JCO's health services and survivorship research portfolio is a real opportunity that many authors overlook. Papers showing that a care delivery intervention improves outcomes, that a survivorship program reduces late effects, or that a cost-effectiveness analysis favors one strategy over another, these are genuinely competitive at JCO.

If your paper isn't a clinical trial but shows clear evidence that oncology practice should change, JCO's editorial scope is broader than most authors assume. The same editorial test applies: does this help an oncologist make a better decision?

Many of the highest-profile JCO papers debut as abstracts at the ASCO Annual Meeting before full publication. This creates a de facto two-stage pipeline: present at ASCO, get visibility, then submit the full manuscript to JCO. If your work has already been presented at an ASCO plenary or oral session, the editorial team is already aware of it. That's not a guarantee of acceptance, but it shortens the path. For work that hasn't been at ASCO, the bar is the same, the paper just needs to stand on the strength of its clinical evidence.

Before submitting, a JCO scope and readiness check can assess whether your paper's clinical action is clear enough for JCO's editorial screen.

JCO (ASCO, IF ~42) is the #1 clinical oncology journal and the flagship of the American Society of Clinical Oncology. The journal publishes practice-changing clinical research: definitive trials, large-scale outcomes data, and guideline-informing evidence.

JCO does not accept basic cancer biology (Cancer Research, Cancer Cell), early-phase trials with uncertain results (too early for this venue), or translational work without clinical endpoints (JCI or Nature Medicine). The editorial question is: will oncologists treat patients differently because of this evidence?

JCO offers a Rapid Review program for time-sensitive findings (request in cover letter). EZSubmit format-free policy. Protocol required for randomized/interventional trials.

A JCO desk-rejection risk check scores fit against the journal's editorial bar.